| close this window |
| Source: | LOHAS Weekly Newsletter |
| Published: | Wednesday, November 27, 2002 |
The herbal directive “seeks to shoehorn herbal remedies into the formal regulatory environment of pharmaceutical drugs and threatens their continued availability,” according to a CHC campaign statement.
Britain stands to lose more than other EU members because it currently offers the most liberal regulatory environment, says NutraIngredients.com. It cites a report in the UK's Financial Times, which values the British herbal market at $704.9 million per year, the biggest in Europe. CHC asserts that if the directive passes, hundreds of herbal products currently available in Britain will have to be removed from shelves.